



Plasma NGAL (Neutrophil Gelatinase Associated Lipocalin) Levels in Septic Patients With & Without Acute Kidney Injury: A Plausible Biomarker

¹Amber Naureen, ²Maryam Rao, ²Farkhanda Naimat, ²Rahat Naseem, ¹Qanita Mahmud, ¹Javaria Zafar

ABSTRACT

Introduction: Acute kidney injury is extremely common among septic patients. Its early recognition among critically ill patients can help in better prognosis and decrease the risk of longer hospital stay and dialysis requirement. Creatinine is considered as a gold standard for diagnosis of Acute Kidney Injury but it has its own disadvantages. New biomarkers for Acute Kidney Injury that can help in its early recognition are the need of time. Many plasma and urinary markers including Neutrophil Gelatinase Associated Lipocalin are being studied. Its role in earlier detection of septic Acute Kidney Injury in septic patients in our set of population still needs extensive research where incidence of sepsis associated complications leading to death is extremely high.

Aims and Objectives: To measure plasma Neutrophil Gelatinase Associated Lipocalin levels in septic patients with and without acute injury compare pNGAL levels in two groups, and to measure specificity and sensitivity of plasma Neutrophil Gelatinase Associated Lipocalin levels in both sets of patients.

Place and Duration of study: A cross sectional analytical study was carried out in National Health Research Complex, Shaikh Zayed Hospital, Lahore over a period of 3 years from 2016-2019

Material and Methods: This is a cross-sectional analytical study carried out in ninety two patients that are divided in two groups on the basis of creatinine levels measured at 72hrs. First group consists of septic patients who developed Acute Kidney Injury (AKI) and second group consists of septic patients Without Acute Kidney Injury(WAKI). Plasma NGAL levels are compared in two groups. SPSS v 20 was used for analysis, p-value ≤ 0.05 was considered significant.

Results: The plasma NGAL level at 24 hours for group without Acute Kidney Injury was 126.4 ± 15.4 ng/ml and for the group which developed Acute kidney Injury was 191.1 ± 15.9 ng/ml and the difference was clearly significant with p-value < 0.001 .

Conclusion: pNGAL levels are significantly raised than the cut-off value of 150ng/ml at 0hrs in septic patients who developed AKI as compared to septic patients who didn't develop AKI.

Key Words: Sepsis, Acute kidney Injury, Plasma NGAL

INTRODUCTION

Acute Kidney Injury is a sudden fall in the kidney function and its foremost cause is sepsis¹. AKI is independently associated with complications, poor prognosis and high mortality². Septic AKI is considered to be a distinct clinical entity. Sepsis is undoubtedly the most prevalent source of AKI today. Different analyses indicate that the incidence of septic AKI occurs between 19 to 48%, while the

mortality of patients with septic AKI varies from 22 to 70%³. Tubular cellular injury is the most important in the contribution to sepsis induced AKI and the main molecular driver of injury is cellular hypoxia⁴. AKI intensity is almost proportional to the graveness of the inflammatory events involved in sepsis and the outcome. Septic AKI also has worse prognosis than non-septic AKI leading to higher mortality⁵. Creatinine and urine output have both been used to diagnose and determine the severity of septic AKI⁶. Specific symptoms that can help in early detection of AKI are lacking. In addition to it, creatinine is an insensitive and late marker for AKI.⁷ Creatinine is affected by race, age, gender, muscle mass, nutrition status, hydration status, medications, catabolic rate and tubular secretion⁸. Serum creatinine has non-linear relationship with GFR and is not considerable as ideal marker for septic AKI as is troponin I considered for the diagnosis of acute myocardial infarction in the adult population⁹.

¹Department of Physiology, Fatima Jinnah Medical University, Lahore.

²Department of Physiology, King Edward Medical University, Lahore.

Correspondence:

Dr. Amber Naureen, Assistant Professor, Fatima Jinnah Medical University, Lahore.

E-mail: amber.naureen@yahoo.com

Submission Date: 28th February 2024

1st Revision Date: 10th April 2024

Acceptance Date: 24th April 2024

NGAL is a rapidly emerging marker for acute kidney injury. It is a small 25kD a protein covalently bound polypeptide from human neutrophils¹⁰. Neutrophil gelatinase associated lipocalin appears in two pools: systemic and renal. In healthy individuals, NGAL is continuously produced in various cell types and is also detectable in small amounts in systemic circulation¹¹. In kidneys, it originates from distal convoluted tubule. It is expressed both in urine and plasma. It is freely filtered in urine through glomerulus¹². It is readily reabsorbed in proximal tubule. So, normally minute amounts are detectable in urine¹⁰. In case of AKI, NGAL is upregulated in ascending limb of loop of Henle, distal tubule and collecting duct leading to secretion from apical and basolateral part of nephron epithelia¹³. Re-absorption from proximal tubule is also impaired in case of proximal tubular injury which causes further increase in urine NGAL levels¹⁴. In septic patient, there are multiple sources of NGAL including extra renal production and release by neutrophils or epithelial cells into the bloodstream followed by glomerular filtration and then excretion in urine as well as increased production by renal tubular epithelial cell and by granulocytes sequestered in tubular lumen¹⁵. Neutrophil gelatinase associated lipocalin can be measured in both blood and urine as a biomarker of AKI¹⁶. Role of pNGAL in septic patients has not been highlighted as required. Specially in Pakistan where the load of sepsis and AKI is much higher and the health care system is still deficient, the earlier diagnosis of septic AKI can definitely reduce the mortality rate and the financial resources requires during prolonged hospital stays.

MATERIAL AND METHODS

A cross sectional analytical study was carried out in National Health Research Complex, Shaikh Zayed Hospital, Lahore over a period of 2 years after approval from the Technical Review Board and the Ethical Committee. (IRB No: 1296). The sample size of eighty patients with expected occurrence of acute kidney injury as 60%. However, taking into account high mortality among septic patients, ninety-two patients with suspected or proven sepsis above the age of 18 years were included and patients with chronic renal insufficiency (sCr>3.0 mg/dl), on dialysis, pregnancy, urothelial, colorectal and pancreatic carcinomas were excluded. An informed consent was taken from each participant in the study. Demographic data was collected by a proforma. Detailed history and examination were carried out. Sepsis was defined as a systemic

inflammatory response due to suspected or proven infection and was considered in the presence of WBC >12x10³/mm³ at presentation and peripheral temperature >38°C persisting for at least 12 hours after presentation. AKI was defined as a 50% increase in serum creatinine levels from the baseline. A 3cc blood sample was collected at 0 hour for complete blood counts and creatinine levels. After normal creatinine levels were received, another 3cc blood sample was drawn for NGAL measurement within 24 hours and transported within an hour for centrifugation to separate plasma. pNGAL estimation was done by Lipocalin 2 (NGAL) Human ELISA kit. pNGAL levels of 150 ng/ml was considered as cut off value. Creatinine levels at 72 hours were again taken to determine whether the patient developed AKI.

Fifty-two patients developed AKI. However, 5 patients died and among the remaining forty-seven patients, forty patients were selected for septic AKI group after gender equalization with septic WAKI group to avoid any bias. Forty patients who developed acute kidney injury were assigned the group as septic AKI group and forty patients who didn't develop AKI were assigned the group as septic WAKI group.

SPSS version 20 was used for data entry and analysis. Serum creatinine at 0 hours and 72 hours was described by using Mean+ SD as well as median, Q1 and Q3 for both groups. Comparisons of creatinine at 0 hours between the groups was made by using Mann-Whitney U test and comparisons of creatinine at 72 hours between two groups was made by independent sample t-test. Data for plasma NGAL levels was described by using frequency and percentages for both groups and was also shown with box graphs. Comparison between the groups was made by independent sample t-test. Sensitivity of pNGAL for AKI at 24 hours was estimated by using ROC curve and was presented by using percentages with 95% confidence interval. p-value ≤ 0.05 was considered significant.

RESULTS

The study comprised ninety-two septic patients divided into two groups; acute kidney injury and without acute kidney injury. The mean±SD of the ages were 44.93±16.60 years for septic AKI and 47.45±15.95 years for septic WAKI. There were 23 males (57.5%) and 17 females (42.5%) in both acute kidney injury and without acute kidney injury group with Male to female ratio of 1.1:1. Regarding plasma NGAL at 24 hours, 40 patients (100%) had 151-226ng/ml plasma NGAL at 24 hours in AKI

and Non-AKI group, 40 patients (100%) had 96-150ng/ml plasma NGAL levels with mean and standard deviations 191.08±15.88 and 126.43±15.35 respectively. (Table-1) shows Frequency and percentage of plasma NGAL at 24 hours in both groups, (Table-2) shows Serum creatinine levels for two groups at baseline and at 72hours and comparison at each time, (Table-3) shows Comparison of plasma NGAL level at 24 hours between two groups, (Table-4) Acute kidney injury status by cut-off of plasma NGAL determined by ROC curve. While the Box plot presenting distribution of plasma NGAL for two groups is shown as Fig-1, the Receiver operative characteristics curve to determine cut-off for serum plasma NGAL level for acute kidney injury is elucidated as Fig-2.

Plasma NGAL at 24 hours	Acute kidney injury (n=40)		Without acute kidney injury (n=40)	
	No. of patients	% of patients	No. of patients	% of patients
96 – 150ng/ml	-	-	40	100.0
151 – 226ng/ml	40	100.0	-	-
Mean ±SD	191.08±15.88ng/ml		126.43±15.35ng/ml	
P-value	.000 (significant)			

Table-1: Frequency and percentage of plasma NGAL at 24 hours in both groups

Creatinine level at	Group of the patients		Test value	P-value
	Acute kidney injury mg/dl	Without AKI mg/dl		
0 hour	Mean	1.2	Mann Whitney U = 620.5	0.080 (insignificant)
	SD	0.3		
	Q1	0.9		
	Median	1.1		
	Q3	1.4		
72 hour	Mean	2.7	t-test= 23.04	<0.001 (significant)
	SD	0.3		
	Q1	2.5		
	Median	2.7		
	Q3	2.9		

Table-2: Serum creatinine levels for two groups at baseline and at 72hours and comparison at each time.

	Group of the patients		t-test	P-value
	Acute kidney injury ng/ml	Without AKI ng/ml		
Mean	191.1	126.4	18.51	<0.001 (significant)
SD	15.9	15.4		
Q1	180.0	114.5		
Median	190.0	129.5		
Q3	203.0	140.0		

Table-3: Comparison of plasma NGAL level at 24 hours between two groups.

Plasma NGAL at 24 hours	Group of the patients					
	Acute kidney injury		Without AKI		Total	
	N	%	N	%	N	%
>150ng/ml	40	100.0	0	0.0	40	50.0
≤ 150ng/ml	0	0.0	40	100.0	40	50.0
Total	40	100.0	40	100.0	80	100.0

Table-4: Acute kidney injury status by cut-off of plasma NGAL determined by ROC curve

The ROC also confirmed non-overlapping with a cut-off 150 ng/ml, for all cases with acute kidney injury. The accuracy for predicting injury at 72 hours, through NGAL at 24 hours, was found 100% at this cut-off.




Fig-1: Box plot presenting distribution of plasma NGAL for two groups




Fig-2: Receiver operative characteristics curve to determine cut-off for serum plasma NGAL level for acute kidney injury

DISCUSSION

Septic AKI takes a toll on overall health system resources and serum creatinine levels used solely as septic AKI marker have significant limitations¹⁷. In this study, it is analysed whether pNGAL holds its role as a biomarker in septic AKI in our population. Two groups each containing forty septic patients are made on the basis of AKI called septic AKI and septic WAKI and their creatinine levels and plasma NGAL levels are compared.

A cut of 150 nanogram per milliliter for plasma NGAL is considered¹⁸. For septic patients in different studies, a value of p NGAL within a range of 150 to 400 ng/ml has been considered¹⁹. The identification of AKI defined as a 50% or greater increase in serum creatinine levels in humans, is first described by Mishra et al and has been used as an AKI diagnostic criteria in a study carried out by Nisha et al²⁰. In the study carried out by Shapiro et al, a total of 661 patients with suspected sepsis were finally analyzed for acute kidney injury. AKI is considered if serum creatinine level arises greater than 0.5mg/dl or acute need for RRT within 72 hours. The median NGAL levels for septic without AKI group carried out by Shapiro et al were 134 ng/ml and for septic AKI plasma NGAL median is 456 ng/ml. Plasma NGAL level in the group with AKI were 3.4 times higher than the plasma NGAL level in non AKI group. pNGAL levels greater than 150 ng/ml have area under curve of 0.82 thus showing that pNGAL is a strong predictor of septic AKI.²¹ So, the results of this study validated the present study. However, the median pNGAL levels are much greater for septic AKI as well as without AKI as compared to those found in this study. Most probable reason being that in the study conducted by

Shapiro et al²¹, the patients included already had a higher creatinine level. In the current study the patients enrolled had normal creatinine levels however their pNGAL levels were still found to be proportionally raised to the level of acute kidney injury. This pointed towards the sensitivity of pNGAL as a biomarker for AKI matching the disease progression.

In a study carried out by Martensson J et al, the impact of sepsis on the concentration of NGAL in plasma and urine in adult ICU patients is analysed along with other biomarkers. The cut-off value for pNGAL is considered 120ng/ml. The median pNGAL value for Systemic inflammatory response syndrome (SIRS) patients without AKI is 111ng/ml, that for severe sepsis patients without AKI is 116ng/ml, and that for septic shock patients without AKI is 134ng/ml. The median pNGAL value for patients with septic shock with AKI is 216ng/ml. So, the difference between the pNGAL value of septic groups with AKI and without AKI is significant²². The results of this study are also comparable with those of this study showing the role of pNGAL as a potential biomarker for septic AKI patients. In the study carried out by Ralib et al, 129 septic patients were taken out of which 67 developed AKI. NGAL concentrations were higher in AKI patients within both the sepsis and SIRS patients (both $P < 0.0001$). AUC for septic AKI was 0.81 (95%CI: 0.74 to 0.87)²³. In the study carried out by Khwaja et al, 48 patients with suspected sepsis were enrolled and plasma NGAL levels were measured at 12 hours and 24 hours and were found to be significantly higher in patients who developed AKI with AUC at 12 hours was 0.82 (95% CI 0.68-0.96) with a sensitivity of 70.8% and specificity of 90.9% thus further validating my study results¹⁹.

This study has some limitations too. Only 80 patients were included. A greater sample size would be better. The time delay in the diagnosis of sepsis should be avoided using a better clinical approach. Temporal changes in the pNGAL should be considered by taking samples at 24 hours and 48 hours. So, further studies are recommended to establish NGAL as a biomarker for septic acute kidney injury patients.

CONCLUSION

This research has analysed the potential role of pNGAL as a more sensitive marker of septic AKI than creatinine. It has been statistically concluded that the plasma NGAL levels in septic patients that developed AKI are significantly higher than those who didn't develop AKI. It is a cost effective test as

it provides highest value for money when compared with the costs of the interventions after AKI has occurred like Renal Replacement Therapy with hemodialysis and peritoneal dialysis. Plasma NGAL levels at a cut-off value of 150ng/ml have shown high sensitivity (100%) and an AUC equal to 1, hence proving it to be a more authentic and dependable marker of Acute Kidney Injury in Septic patients and deleterious effects of AKI in septic patient can thus be prevented.

REFERENCES

1. Xu L, Sun P. Identification and management of sepsis associated-acute kidney injury. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue*. 2023 Feb;35(2):221-224.
2. Mercado MG, Smith DK, Guard EL. Acute Kidney Injury: Diagnosis and Management. *Am Fam Physician*. 2019 Dec 1;100(11):687-694.
3. Yang Y, Dong J, Chen X, Chen R, Wang H. Incidence, risk factors and clinical outcomes of septic acute renal injury in cancer patients with sepsis admitted to the ICU: A retrospective study. *Front Med (Lausanne)*. 2022 Dec 14;9:1015735.
4. Aslan A, van den Heuvel MC, Stegeman CA, et al. Kidney histopathology in lethal human sepsis. *Crit Care*. 2018;22:359.
5. Peerapornratana S, Manrique-Caballero CL, Gómez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. *Kidney Int*. 2019 Nov;96(5):1083-1099.
6. Zarbock A, Nadim MK, Pickkers P, Gomez H, Bell S, Joannidis M, Kashani K, Koyner JL, Pannu N, Meersch M, Reis T. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. *Nat Rev Nephrol*. 2023 Jun;19(6):401-417.
7. Chang YM, Chou YT, Kan WC, Shiao CC. Sepsis and Acute Kidney Injury: A Review Focusing on the Bidirectional Interplay. *Int J Mol Sci*. 2022 Aug 15;23(16):9159.
8. Chen L, Wu X, Qin H, Zhu H. The PCT to Albumin Ratio Predicts Mortality in Patients With Acute Kidney Injury Caused by Abdominal Infection- Evoked Sepsis. *Frontiers in Nutrition*. 2021;8(179).
9. Ragán D, Horváth-Szalai Z, Szirmay B, Mühl D. Novel Damage Biomarkers of Sepsis-Related Acute Kidney Injury. *EJIFCC*. 2022 Apr 11;33(1):11-22.
10. Romejko K, Markowska M, Niemczyk S. The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL). *Int J Mol Sci*. 2023 Jun 21;24(13):10470.
11. Chen J.J., Lee T.H., Lee C.C., Chang C.H. Using lipocalin as a prognostic biomarker in acute kidney injury. *Expert. Rev. Mol. Diagn*. 2021;21:455-464.
12. Wen Y., Parikh C.R. Current concepts and advances in biomarkers of acute kidney injury. *Crit. Rev. Clin. Lab. Sci*. 2021;58:354-368.
13. Ntrinas T., Papasotiriou M., Balta L., Kalavrizioti D., Vamvakas S., Papachristou E., Goumenos D.S. Biomarkers in Progressive Chronic Kidney Disease. Still a Long Way to Go. *Prilozi*. 2019;40:27-39.
14. Mathieu Buonafine , Ernesto Martinez-Martinez, Frédéric Jaisser. More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases *Review Clin Sci (Lond)* . 2018 May 8;132(9):909-923.
15. Gomes BC, Silva Júnior JM, Tuon FF. Evaluation of Urinary NGAL as a Diagnostic Tool for Acute Kidney Injury in Critically Ill Patients With Infection: An Original Study. *Can J Kidney Health Dis*. 2020 Jun 19;7:2054358120934215.
16. Törnblom S, Nisula S, Petäjä L, Vaara ST, Haapio M, Pesonen E, Pettilä V; FINNAKI study group. Urine NGAL as a biomarker for septic AKI: a critical appraisal of clinical utility-data from the observational FINNAKI study. *Ann Intensive Care*. 2020 Apr 28;10(1):51.
17. Molinari L, Del Rio-Pertuz G, Smith A, Landsittel DP, Singbartl K, Palevsky PM, Chawla LS, Huang DT, Yealy DM, Angus DC, Kellum JA; ProCESS and ProGRess-AKI Investigators. Utility of Biomarkers for Sepsis-Associated Acute Kidney Injury Staging. *JAMA Netw Open*. 2022 May 2;5(5)
18. Nikolas T, O' Rourke M, Yang J, Meghan E, et al. Sensitivity and specificity of single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. *Annals of Internal Medicine*. 2008;148:810-19.
19. Khawaja, S., Jafri, L., Siddiqui, I. et al. The utility of neutrophil gelatinase-associated Lipocalin (NGAL) as a marker of acute kidney injury (AKI) in critically ill patients. *Biomark Res* 7, 4 (2019). <https://doi.org/10.1186/s40364-019-0155-1>
20. Bansal N, Matheny ME, Greevy RA Jr, Eden SK, Perkins AM, Parr SK, Fly J, Abdel-Kader K, Himmelfarb J, Hung AM, Speroff T, Ikizler TA, Siew ED. Acute Kidney Injury and Risk of Incident Heart Failure Among US Veterans. *Am J Kidney Dis*. 2018 Feb;71(2):236-245.
21. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, et al. The diagnostic accuracy of plasma neutrophil gelatinase – associated lipocalin in the prediction of acute kidney injury in emergency department patients with suspected sepsis. *Infect Dis*. 2010;56(1):52-9.
22. Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. *Intensive Care Med*. 2010; 36:1333-40.
23. Md Ralib A, Mat Nor MB, Pickering JW. Plasma Neutrophil Gelatinase-Associated Lipocalin diagnosed acute kidney injury in patients with systemic inflammatory disease and sepsis. *Nephrology (Carlton)*. 2017 May;22(5):412-419

The Authors:

Dr. Amber Naureen,
Assistant Professor,
Department of Physiology,
Fatima Jinnah Medical University, Lahore.

Dr. Maryam Rao,
Associate Professor,
Department of Physiology,
King Edward Medical University, Lahore.

Dr. Farkhanda Naimat,
Demonstrator,
Department of Physiology,
King Edward Medical University, Lahore.

Dr. Rahat Naseem,
Assistant Professor,
Department of Physiology,
King Edward Medical University, Lahore.

Dr. Qanita Mahmud,
Associate Professor,
Department of Physiology,
Fatima Jinnah Medical University, Lahore.

Dr. Javaria Zafar,
Demonstrator,
Department of Physiology,
Fatima Jinnah Medical University, Lahore.

Authorship:

AN: Manuscript writing, idea

MR: Data collection

FN: Data collection

RN: Analysis and interpretation of results

QM: Analysis and interpretation of results

JZ: Editing